Abstract:Abstract Introduction DNA methyltransferase (DNMT) family play an important role in the development and growth of lives, encoding enzymes that catalyze the addition of a methyl group to the cytosine residue of CpG islands. With the increase in methylation, the downstream genes are often associated with reduced expression. In this family, DNMT3a occupies the essential position to implement the de novo methylation. Timothy J. Ley and many other scientists found that in M4 and M5 acute myeloid leukemia (AML), around 20% patients suffered from DNMT3a mutation (most are R882H mutation), always associating with adverse prognosis. But what's the reason for adverse prognosis? Additionally, our formal Meta analysis showed that the de novo AML patients with DNMT3a mutation have higher platelet counts, WBC and RBC counts. To shed some light on the possible causal relation between the increasing in platelet count and poor prognosis led by DNMT3a mutation, we transduced the MK cell lines with genes null-mCherry (null), DNMT3a wild type-mCherry (DNMT3aWT) and DNMT3a R882H mutation type-mCherry (DNMT3aMT) respectively, trying to figure out the possible role that the mutation plays in the megakaryopoiesis and thrombopoiesis. Also, we tested several drugs that may target the mutation. Methods The SFFV-null-IRES-mCherry, SFFV-DNMT3aWT-IRES-mCherry and SFFV-DNMT3aMT-IRES-mCherry plasmids were constructed by Dr. Qianli Jiang, modified from LEGO-iC plasmids. MK cell lines (chrf-288-11, meg-01) were flow-through transduced with the lentivirus produced by packaging plasmids and those above. All the fluorescence positive cells have been doubly sorted by flow cytometry. Cell ploidy was analyzed by flow cytometry using Propidium Iodide (PI); colony forming unit (CFU-MK) were enumerated 14d after being plated with TPO and IL-3; cell proliferation were tested by CCK-8; apoptosis was measured via flow cytometry with PI and Annexin V-FITC; CD41a and CD61 were tested with flow cytometry. The drug tests including Decitabine, Dasatinib and Rituximab were analyzed using CCK-8 test and cytomorphologic tests. Results With CCK8 test of chrf-288-11 and meg-01, DNMT3aMT proliferates faster than the null and DNMT3aWT (P<0.05, Fig.1). In CFU-MK, both cells lines showed that DNMT3a mutation promoted the colony formation (P<0.05). The CD41a percentage decreased from null to DNMT3aWT and DNMT3aMT (P<0.05) while the CD61percentage increased from null to DNMT3aWT and DNMT3aMT (P<0.05). Also, with morphologic analyses, DNMT3aMT in both cell lines maintain more mature stages. Cell ploidy test also demonstrated that cell lines with DNMT3a mutation contain more multiploids (P<0.05). Apoptosis test illustrated that DNMT3a mutation protect the cell lines from apoptosis (P<0.05). In the drug experiments, 1uM Decitabine could slow down the proliferation of 3 gene types of chrf-288-11 significantly (P<0.05). Dasatinib also posed a negative effect on the proliferation of 3 gene types of chrf-288-11 (P<0.05, Fig.2). In Rituximab experiment, we could find that interestingly, certain concentrations could speed up the proliferation of 3 gene types of chrf-288-11, while others not (P<0.05, Fig.3). Conclusion With all the above evidences, we can safely conclude that the megakaryocyte cell lines with DNMT3a mutation are associated with high-differentiation, high-colony formation and low-apoptosis, which could help us to understand the elevation of platelet count in AML patients with DNMT3a mutation. The anti-apoptosis and renewal ability of the cell lines with DNMT3a mutation may lead to a bad prognosis of these AML patients (with DNMT3a mutation). What's more, according to the drug experiment, we found in the both cell lines, DNMT3aWT and DNMT3aMT cells died significantly at even low concentration of decitabine. Dasatinib also slowed down the proliferation of 3 gene types of chrf-288-11, whether Dasatinib could lead to further treatment of such leukemia with DNMT3A mutation needs more research. Rituximab is helpful in the treatment against refractory thrombocytopenia. However, the mechanism hasn't been clarified. Interestingly, our results showed that, Rituximab may have a direct effect on MKs, giving a boost to the megakaryopoiesis and thrombopoiesis with certain concentration. Figure 1 Figure 1. Figure 2 Figure 2. Figure 3 Figure 3. Disclosures No relevant conflicts of interest to declare.

Novel Impact Of The Dnmt3a R882h Mutation On Gsh Metabolism In A K562 Cell Model Established By Talens

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Glutamate Dehydrogenase 1: A Novel Metabolic Target in Inhibiting Acute Myeloid Leukaemia Progression.

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

3141 – LEUKEMIA-ASSOCIATED MUTATIONS IN DNMT3A MEDIATE SENSITIVITY TO REPLICATION STRESS INDUCED BY NUCLEOSIDE ANALOGS

Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Clinical Features and MicroRNA Expression Patterns Between AML Patients with DNMT3A R882 and Frameshift Mutations

Dnmt3a Haploisufficiency Cooperates with Oncogenic Kras to Promote an Early-Onset T-Cell Leukemia

Tet2 Downregulation Leads To Aml Cells Sensitive To Decitabine

Dnmt3a Arg882 Mutation Drives Chronic Myelomonocytic Leukemia Through Disturbing Gene Expression/Dna Methylation in Hematopoietic Cells

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

DNMT3A R882 mutation in children with acute myeloid leukemia and its role in prognosis

DNMT3A Mutation Leads to Hematopoietic Dysregulation.

DNMT3A-R882: a mutation with many paradoxes

DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction Between EZH2 and DNMT3A.

Conditional Knockin Of Dnmt3a R878h Initiates Acute Myeloid Leukemia With Mtor Pathway Involvement

DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming

The Effect of the R882H DNMT3a Mutation on Megakaryocyte Cell Lines

Allogeneic Hematopoietic Stem Cell Transplantation Could Improve Survival of Cytogenetically Normal Adult Acute Myeloid Leukemia Patients with Dnmt3a Mutations